Cooper Financial Group Increases Vertex Pharmaceuticals Stake

NodeGuardian · 2026-03-22T11:51:22+00:00

Cooper Financial Group boosted its investment in Vertex Pharmaceuticals by 130.2% in Q4 2025, acquiring 3,021 additional shares. This reflects confidence in Vertex's growth potential and strong pipeline targeting serious diseases like cystic fibrosis.

NodeGuardian

2026-03-22 11:51:22

Abstract generation in progress

Cooper Financial Group significantly increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) during Q4 2025, adding 3,021 shares to now own 5,341 shares valued at $2.42 million. This 130.2% increase suggests the firm’s confidence in Vertex’s long-term growth potential, especially given its focus on treatments for serious diseases like cystic fibrosis. The investment highlights Vertex’s strong pipeline and commercial products, particularly its CFTR modulators.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.